Lung Cancer
Conditions
Keywords
Tomotherapy, Toxicity
Brief summary
Lung cancers treated by Tomotherapy represent between 60 and 100 patients per year at the CHR of Metz-Thionville. Some patients were observed to present acute toxicities during treatment such as dysphagia or esophagitis of CTCAE grade \> 2. Beyond well known therapeutic and comorbidities factors, the pathophysiology of these events is largely ruled by a constitutional factor - the enzymatic equipment allowing more or less good repair of the DNA lesions induced by radiotherapy (RT). This equipment is characteristic of each individual, hence the term individual radiosensitivity (IR).The scientific literature is rather poor in data describing the frequency of these toxicities in patients receiving RT for lung cancer. The objective of this study is to describe the frequency of acute and late toxicities after normofractionated radiotherapy of 66 Gy in 33 fractions in patients with small cell or non-small cell lung cancer, stage 2 or 3.
Interventions
None listed
Sponsors
Centre Hospitalier Régional Metz-Thionville
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* stage II-III non-small cell or small cell lung cancer treated with normo-fractionated radiotherapy of 66Gy in 33 fractions using Tomotherapy
Exclusion criteria
* patient who refused to be included in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| late toxicity of radiotherapy | up to 2 years after tomotherapy treatment | according to CTCAE v5.0 grading |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| acute toxicity of radiotherapy | 6 months following tomotherapy treatment | according to CTCAE v5.0 grading |
Countries
France
Outcome results
None listed